ABS Blog

New Castle, DE —December 5, 2024  —  ABS Bio, Inc., a leader in biospecimen sourcing, cell culture services and biostorage for the global pharmaceutical and biotechnology industry, today announced a strategic refresh of its corporate brand identity.

New Castle, DE — November 14, 2024  —  ABS Bio, Inc., a leader in biospecimen sourcing, cell culture services and biostorage for the global pharmaceutical and biotechnology industry, today announced a strategic investment by 3 Boomerang Capital, a Greenwich, CT based healthcare-focused private equity firm. The investment will position ABS Bio to accelerate enhancements to its service offerings while growing its reach among biopharma R&D professionals.  ABS also announced an expanded board of directors, including John Chickosky as Executive Chairman, and Greg Swanberg and Martin LeBlanc as Directors.